timothy sykes logo
PBM Surges As Psyence Biomedical Rides Ibogaine Policy Wave Thumbnail
G Google News

PBM Surges As Psyence Biomedical Rides Ibogaine Policy Wave

TIM SYKES•UPDATED APR. 18, 2026, 10:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Psyence Biomedical Ltd. stocks have been trading up by 44.8 percent following highly positive coverage of its psychedelic therapies pipeline.

Candlestick Chart

Weekly Update Apr 13 – Apr 17, 2026: On Saturday, April 18, 2026 Psyence Biomedical Ltd. stock [NASDAQ: PBM] is trending up by 44.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Psyence Biomedical is a micro-cap psychedelic therapeutics and ibogaine manufacturing platform, not a traditional PBM, with essentially no operating scale relative to Healthcare benchmarks. The balance sheet is unusually cash-heavy (cash and equivalents of ~$6.2M against total liabilities of only ~$0.6M), yielding very low leverage (liabilities/assets ~8%; leverage ratio 1.1) and ample working capital. However, extreme accounting volatility is evident: ROA of -205.9% and ROIC -48% reflect tiny equity capital and cumulative losses, implying continued equity dilution risk despite asset backing.

Technically, the stock has transitioned from an illiquid, tight range (2.79–2.96 over several sessions) into a momentum breakout, with price spiking from ~2.8 to intraday highs above 9 on surging volume following policy headlines. The dominant trend on the weekly tape is now strongly bullish, but short-term overextended. The key actionable level is the 7.40–7.60 zone, which acted as intraday support after the spike; a sustained hold above 7.50 favors continuation toward 9.50–10, while a decisive break below 7.40 likely triggers mean reversion toward 5.

Fundamentally, Psyence is now tightly tethered to U.S. ibogaine policy risk. The reported executive-order initiative and the company’s GMP ibogaine and NPX-5 infrastructure position it to outperform typical Biotechnology & Life Sciences peers on regulatory upside, but its micro-cap, single-theme profile makes it riskier than diversified Healthcare benchmarks. Near term, I expect elevated volatility with a constructive bias; support sits at 7.50, resistance at 10.00. On a 6–12 month view, a disciplined but speculative upside target is 11–12.

Quick Financial Overview

Psyence Biomedical Ltd. (PBM) just showed traders what a true news-driven breakout looks like. Weekly data show PBM pinned around the mid-$2 zone from 2026/04/13 to 2026/04/15, then exploding to an $8.18 close on 2026/04/16 and holding $8.50 on 2026/04/17. That is a multi-bagger move in days, tied directly to expectations around a potential U.S. executive order on ibogaine research rather than any new clinical readout.

Intraday, the 5-minute snapshot tells the same story in micro. Price opened near $9.82, spiked to $10.53, then flushed to $7.11 and stabilized around $7.60. For short-term traders, this kind of wide intraday range signals high volatility and likely heavy speculative flow. PBM is behaving like a momentum-driven biotech, not a slow, steady compounder.

More Breaking News

On the fundamentals side, the key ratios paint a classic early-stage, high-risk profile. Enterprise value is only about $1.60M, with price-to-book near 0.89 and book value per share around $6.58, implying the stock, even after the spike, is not wildly above stated equity. The latest balance sheet (period ending 2025/03/31) shows roughly $6.17M in cash against only about $0.59M in total liabilities and working capital near $5.97M, which gives Psyence Biomedical Ltd. some runway. However, extreme negative return on assets and a deeply negative retained earnings balance confirm that PBM is still very much in the capital-consuming, pre-profit stage.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading PBM

Millionaire's
POV on PBM

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”